Identifying and validating novel targets with in vivo disease models:: Guidelines for study design

被引:12
作者
Anders, Hans-Joachim [1 ]
Vielhauer, Volker [1 ]
机构
[1] Univ Munich, Med Poliklin, D-80336 Munich, Germany
关键词
D O I
10.1016/j.drudis.2007.04.001
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
In vivo studies are an important tool for the identification and validation of novel drug targets in medicine; however, the interpretation of submitted and published data is often compromised by inadequate study design. Different study protocols, including the number of control groups and group size calculations, differ in target identification and validation studies. Furthermore, animal studies require that the selected target or compound meets the requirements for species specificity and target specificity; thus, providing the rationale for the selection of a particular species, strain, gender and age of the animals is necessary. Altogether, the presentation of target validation studies should meet defined criteria similar to those used in human trials.
引用
收藏
页码:446 / 451
页数:6
相关论文
共 37 条
[1]
A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation [J].
Anders, HJ ;
Vielhauer, V ;
Frink, M ;
Linde, Y ;
Cohen, CD ;
Blattner, SM ;
Kretzler, M ;
Strutz, F ;
Mack, M ;
Gröne, HJ ;
Onuffer, J ;
Horuk, R ;
Nelson, PJ ;
Schlöndorff, D .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (02) :251-259
[2]
Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat [J].
Benigni, A ;
Zoja, C ;
Corna, D ;
Zatelli, C ;
Conti, S ;
Campana, M ;
Gagliardini, E ;
Rottoli, D ;
Zanchi, C ;
Abbate, M ;
Ledbetter, S ;
Remuzzi, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1816-1824
[3]
Dual role of CCR2 during initiation and progression of collagen-induced arthritis:: Evidence for regulatory activity of CCR2+ T cells [J].
Brühl, H ;
Cihak, J ;
Schneider, MA ;
Plachy, J ;
Rupp, T ;
Wenzel, I ;
Shakarami, M ;
Milz, S ;
Ellwart, JW ;
Stangassinger, M ;
Schlöndorff, D ;
Mack, M .
JOURNAL OF IMMUNOLOGY, 2004, 172 (02) :890-898
[4]
Systems biology in drug discovery [J].
Butcher, EC ;
Berg, EL ;
Kunkel, EJ .
NATURE BIOTECHNOLOGY, 2004, 22 (10) :1253-1259
[5]
Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation [J].
Chatterjee-Kishore, M ;
Miller, CP .
DRUG DISCOVERY TODAY, 2005, 10 (22) :1559-1565
[6]
Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus [J].
Christensen, SR ;
Kashgarian, M ;
Alexopoulou, L ;
Flavell, RA ;
Akira, S ;
Shlomchik, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (02) :321-331
[7]
Cohen J., 1988, POWERSTATISTICALSCIE, DOI 10.4324/9780203771587
[8]
Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome [J].
Cosgrove, D ;
Meehan, DT ;
Grunkemeyer, JA ;
Kornak, JM ;
Sayers, R ;
Hunter, WJ ;
Samuelson, GC .
GENES & DEVELOPMENT, 1996, 10 (23) :2981-2992
[9]
Conditional ablation of macrophages halts progression of crescentic glomerulonephritis [J].
Duffield, JS ;
Tipping, PG ;
Kipari, T ;
Cailhier, JF ;
Clay, S ;
Lang, R ;
Bonventre, JV ;
Hughes, J .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 167 (05) :1207-1219
[10]
Dytham C., 2003, CHOOSING USING STAT, VSecond